NO20026032D0 - Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer - Google Patents

Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer

Info

Publication number
NO20026032D0
NO20026032D0 NO20026032A NO20026032A NO20026032D0 NO 20026032 D0 NO20026032 D0 NO 20026032D0 NO 20026032 A NO20026032 A NO 20026032A NO 20026032 A NO20026032 A NO 20026032A NO 20026032 D0 NO20026032 D0 NO 20026032D0
Authority
NO
Norway
Prior art keywords
annealed
farnesyltransferase inhibiting
quinoline enantiomer
enantiomer
quinoline
Prior art date
Application number
NO20026032A
Other languages
English (en)
Other versions
NO324494B1 (no
NO20026032L (no
Inventor
Marc Gaston Venet
Patrick Rene Angibaud
David William End
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20026032L publication Critical patent/NO20026032L/no
Publication of NO20026032D0 publication Critical patent/NO20026032D0/no
Publication of NO324494B1 publication Critical patent/NO324494B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Surgery (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20026032A 2000-06-22 2002-12-16 Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer, farmasoytisk sammensetning inneholdende denne og dens fremstilling, samt anvendelse av forbindelsen NO324494B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00202181 2000-06-22
PCT/EP2001/006747 WO2001098302A1 (en) 2000-06-22 2001-06-13 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer

Publications (3)

Publication Number Publication Date
NO20026032L NO20026032L (no) 2002-12-16
NO20026032D0 true NO20026032D0 (no) 2002-12-16
NO324494B1 NO324494B1 (no) 2007-10-29

Family

ID=8171675

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20026032A NO324494B1 (no) 2000-06-22 2002-12-16 Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer, farmasoytisk sammensetning inneholdende denne og dens fremstilling, samt anvendelse av forbindelsen

Country Status (34)

Country Link
US (3) US20030114471A1 (no)
EP (1) EP1296984B1 (no)
JP (1) JP4919575B2 (no)
KR (2) KR100846370B1 (no)
CN (1) CN1207296C (no)
AR (1) AR030704A1 (no)
AT (1) ATE294804T1 (no)
AU (3) AU6396201A (no)
BG (1) BG65894B1 (no)
BR (1) BRPI0111743B8 (no)
CA (1) CA2410232C (no)
CZ (1) CZ295278B6 (no)
DE (1) DE60110592T2 (no)
EA (1) EA005065B1 (no)
EE (1) EE04966B1 (no)
EG (1) EG24180A (no)
ES (1) ES2241830T3 (no)
HK (1) HK1058363A1 (no)
HR (1) HRP20020989B1 (no)
HU (1) HU229095B1 (no)
IL (2) IL153560A0 (no)
IS (1) IS2596B (no)
JO (1) JO2361B1 (no)
MX (1) MXPA02012845A (no)
MY (1) MY127734A (no)
NO (1) NO324494B1 (no)
NZ (1) NZ522481A (no)
PA (1) PA8519501A1 (no)
PL (1) PL209521B1 (no)
SA (1) SA01220349B1 (no)
SK (1) SK285699B6 (no)
UA (1) UA73572C2 (no)
WO (1) WO2001098302A1 (no)
ZA (1) ZA200210305B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003018135A1 (en) * 2001-08-24 2003-03-06 Wyeth Holdings Corporation Method of using 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
ATE336496T1 (de) 2002-04-15 2006-09-15 Janssen Pharmaceutica Nv Farnesyl transferase hemmende tricyclische quinazolinederivate substitutiert mit kohlenstoff-gebundenen imidazolen oder triazolen
US20050003422A1 (en) 2003-07-01 2005-01-06 Mitch Reponi Methods for assessing and treating cancer
US10076512B2 (en) 2014-05-01 2018-09-18 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US11311519B2 (en) 2014-05-01 2022-04-26 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
US20180338993A1 (en) * 2014-12-04 2018-11-29 Eiger Biopharmaceuticals, Inc. Treatment of hepatitis delta virus infection
KR102514971B1 (ko) 2015-04-21 2023-03-27 아이거 바이오파마슈티컬스 인코포레이티드 로나파르닙 및 리토나버를 포함하는 약제 조성물
HUE049620T2 (hu) 2015-08-17 2020-09-28 Kura Oncology Inc Módszerek rákos páciensek kezelésére farneziltranszferáz inhibitorokkal
ES2863730T3 (es) 2016-11-03 2021-10-11 Kura Oncology Inc Inhibidores de la farnesiltransferasa para uso en el tratamiento del cáncer

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1519765A (en) * 1974-09-05 1978-08-02 Ici Ltd Pesticidal dihydrotetrazolo(1,5a) quinazolines compositions and processes
US4141979A (en) * 1976-12-23 1979-02-27 Pfizer Inc. Tetrazolo[a]quinazol-5-ones antiallergy and antiulcer agents
GB9513577D0 (en) * 1995-07-04 1995-09-06 Brotherwood Rodney J Improvements in passenger carrying vehicles
TW349948B (en) * 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
CA2231105C (en) * 1995-12-08 2005-09-13 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
AU715658B2 (en) 1996-04-03 2000-02-10 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
TW591030B (en) * 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
ATE366250T1 (de) * 1997-04-25 2007-07-15 Janssen Pharmaceutica Nv Chinazolinone die farnesyltransferase hemmen
PT988038E (pt) 1997-06-02 2002-12-31 Janssen Pharmaceutica Nv Derivados (imidazol-5-il)metil-2-quinolinona como inibidores da proliferacao de celulas dos musculos lisos
DK1094839T3 (da) * 1998-07-06 2003-08-18 Janssen Pharmaceutica Nv Farnesylproteintransferaseinhibitorer med in vivo radiosensibiliserende egenskaber
EE04579B1 (et) 1998-07-06 2006-02-15 Janssen Pharmaceutica N.V. Farnesüülproteiintransferaasi inhibiitorite kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nähtud artropaatiate raviks
AU4925499A (en) * 1998-08-27 2000-03-21 Pfizer Products Inc. Alkynyl-substituted quinolin-2-one derivatives useful as anticancer agents
BR9913315A (pt) * 1998-08-27 2001-05-22 Pfizer Prod Inc Derivados de quinolin-2-ona úteis como agentes anticâncer
WO2000039082A2 (en) * 1998-12-23 2000-07-06 Janssen Pharmaceutica N.V. 1,2-annelated quinoline derivatives
US6462201B1 (en) * 1998-12-29 2002-10-08 Isp Investments Inc. Process for the production of N-vinyl-2-pyrrolidone by vinylation
CN1340051A (zh) * 1999-02-11 2002-03-13 辉瑞产品公司 可用作抗癌剂的杂芳基取代的喹啉－2－酮衍生物
HN2000000266A (es) 2000-01-21 2001-05-21 Pfizer Prod Inc Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto.
CA2397558A1 (en) * 2000-02-24 2001-08-30 Janssen Pharmaceutica N.V. Dosing regimen
JP4974438B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリンおよびキナゾリン誘導体
JP4974439B2 (ja) 2000-09-25 2012-07-11 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ ファルネシルトランスフェラーゼを阻害する６−ヘテロシクリルメチルキノリノン誘導体

Also Published As

Publication number Publication date
KR100831940B1 (ko) 2008-05-23
CN1207296C (zh) 2005-06-22
CZ2003114A3 (cs) 2003-05-14
IS2596B (is) 2010-03-15
EP1296984A1 (en) 2003-04-02
AU2006220405A1 (en) 2006-10-12
DE60110592T2 (de) 2006-01-19
NO324494B1 (no) 2007-10-29
IL153560A (en) 2011-06-30
EE04966B1 (et) 2008-02-15
PL209521B1 (pl) 2011-09-30
JP2004501153A (ja) 2004-01-15
SK285699B6 (sk) 2007-06-07
SA01220349B1 (ar) 2007-01-23
HUP0300872A2 (hu) 2003-07-28
NO20026032L (no) 2002-12-16
EA005065B1 (ru) 2004-10-28
ZA200210305B (en) 2004-03-19
MXPA02012845A (es) 2003-05-15
US8329714B2 (en) 2012-12-11
HK1058363A1 (en) 2004-05-14
DE60110592D1 (de) 2005-06-09
SK502003A3 (en) 2003-05-02
ES2241830T3 (es) 2005-11-01
IS6590A (is) 2002-10-25
ATE294804T1 (de) 2005-05-15
EP1296984B1 (en) 2005-05-04
EE200200695A (et) 2004-06-15
UA73572C2 (en) 2005-08-15
WO2001098302A1 (en) 2001-12-27
US20080114009A1 (en) 2008-05-15
NZ522481A (en) 2004-09-24
PL358918A1 (en) 2004-08-23
BRPI0111743B1 (pt) 2019-03-26
KR20070121847A (ko) 2007-12-27
CA2410232C (en) 2008-10-07
KR20030009463A (ko) 2003-01-29
AR030704A1 (es) 2003-09-03
HU229095B1 (en) 2013-07-29
CA2410232A1 (en) 2001-12-27
BG107310A (bg) 2003-07-31
CZ295278B6 (cs) 2005-06-15
US8318753B2 (en) 2012-11-27
EG24180A (en) 2008-09-28
US20070259902A1 (en) 2007-11-08
JP4919575B2 (ja) 2012-04-18
JO2361B1 (en) 2006-12-12
BRPI0111743B8 (pt) 2021-05-25
KR100846370B1 (ko) 2008-07-15
CN1437601A (zh) 2003-08-20
HRP20020989A2 (en) 2005-02-28
IL153560A0 (en) 2003-07-06
AU2006220405B2 (en) 2009-05-21
HRP20020989B1 (en) 2011-05-31
AU6396201A (en) 2002-01-02
US20030114471A1 (en) 2003-06-19
MY127734A (en) 2006-12-29
BG65894B1 (bg) 2010-04-30
EA200300048A1 (ru) 2003-04-24
PA8519501A1 (es) 2002-08-29
BR0111743A (pt) 2003-07-08
AU2001263962B2 (en) 2006-07-20
HUP0300872A3 (en) 2004-11-29

Similar Documents

Publication Publication Date Title
RS99203A (en) Pyrrolopyrimidines as protein kinase inhibitors
NZ517758A (en) Pyrazolopyrimidines useful as therapeutic agents
PL377821A1 (pl) 2,4,6-tripodstawione pirymidyny jako inhibitory kinazy fosfatydyloinozytolu (PI) 3 i ich zastosowanie w leczeniu nowotworu
DE60026538D1 (de) Pharmazeutische zubereitungen die clavulansäure oder derivate enthalten zur behandlund von neurologischen störungen
WO2005023759A3 (en) Heterocyclic inhibitors of mek and methods of use thereof
TW200505924A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
BG108268A (en) Pyrazolopyrimidines as therapeutic agents
WO2005011655A3 (en) Pyridazine derivatives and their use as therapeutic agents
GEP20053688B (en) Substituted-Triazolopyrimidines as Anticancer Agents
GB0005251D0 (en) Therapeutic compounds
RS51123B (sr) Aril fuzionisana azapoliciklična jedinjenja
AP2003002929A0 (en) Pyrrolopyrimidines as protein kinase inhibitors
YU4903A (sh) N-/5-///5-alkil-2-oksazolil/metil/tio/-2-tiazolil/ karboksamidni inhibitori ciklin zavisnih kinaza
IS6970A (is) Lyfjablanda á föstu formi sem felur í sér 4-sýanó-tríflúor-3-(4-flúorfenýlsúlfonýl)-2-hýdroxý-2-metýlprópíón-m-tólúidíð og PVP
ATE396986T1 (de) Pyrimidylpyrrolderivate, die als kinaseinhibitoren wirken
MXPA05013628A (es) Pirazolo[3,4-b]piridin-6-onas como inhibidores de gsk-3.
AU2972701A (en) 3-aminopyrazole inhibitors of cyclin dependent kinases
NO20026032D0 (no) Farnesyltransferasehemmende 1,2-annelert kinolinenantiomer
DE60108626D1 (de) Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
MXPA02008870A (es) Novedosos antagonistas de lhrh, produccion de los mismos y sus uso como medicamentos.
TH59553B (th) 1,2-แอนเนเลเทด ควิโนลีน อิแนนซิโอเมอร์ ซึ่งมีฤทธิ์ยับยั้งฟาร์เนซิลทรานส์เฟอเรส
WO2003066806A3 (en) Therapeutic use of aziridino compounds

Legal Events

Date Code Title Description
MK1K Patent expired